A Randomized, Open-label, Two-way Crossover Study Assessing the Bioequivalence (BE) Between Single Dose of 750 mg Glucophage XR Tablets (PT Merck Tbk, Jakarta, Indonesia-Manufactured) and 750 mg Glucophage XR Tablets (Merck Santé, Semoy, France-Manufactured) Under Fasted State in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2018
At a glance
- Drugs Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 15 Oct 2018 Status changed from recruiting to completed.
- 06 Sep 2018 Status changed from not yet recruiting to recruiting.
- 25 Jul 2018 Planned End Date changed from 31 Aug 2018 to 27 Sep 2018.